Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.

Many Medicare drug plans cover generic epinephrine auto-injectors, and some may also cover EpiPen. Medicare coverage through a Part D prescription drug plan depends on the plan details and other ...

The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.